- Indicated in patients for whom treatment with both amlodipine and atorvastatin is appropriate.
Amlodipine
- Treatment of hypertension, to lower blood pressure
- Coronary Artery Disease (CAD)
- Symptomatic treatment of chronic stable angina
- Treatment of confirmed or suspected vasospastic angina (Prinzmetal's or Variant Angina)
- Angiographically documented CAD
- To reduce the risk for hospitalization for angina and to reduce the risk of coronary revascularization procedure in patients with recently documented CAD by angiography and without heart failure or an ejection fraction <40%
Atorvastatin
- Prevention of Cardiovascular Disease:
- Reduce the risk of myocardial infarction, reduce the risk of stroke and reduce the risk for revascularization procedures and angina in adult patients without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as age, smoking, hypertension, low high-density lipoprotein cholesterol (HDL-C), or a family history of early coronary heart disease
- Reduce the risk of myocardial infarction and reduce the risk of stroke in patients with type 2 diabetes, and without clinically evident coronary heart disease, but with multiple risk factors for coronary heart disease such as retinopathy, albuminuria, smoking, or hypertension
- Reduce the risk of non-fatal myocardial infarction, reduce the risk of fatal and non-fatal stroke, reduce the risk for revascularization procedures, reduce the risk of hospitalization for congestive heart failure (CHF), and reduce the risk of angina in patients with clinically evident coronary heart disease
- Hyperlipidemia
- Heterozygous Familial and Nonfamilial Hypercholesterolemia:
- As an adjunct to diet to reduce elevated total-cholesterol (C), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (apo B), and triglyceride (TG) levels and to increase HDL-C in patients with primary hypercholesterolemia (heterozygous familial and nonfamilial) and mixed dyslipidemia (Fredrickson types IIa and IIb)
- Elevated Serum TG (triglyceride) levels:
- As an adjunct to diet for the treatment of patients with elevated serum TG levels (Fredrickson type IV)
- Primary Dysbetalipoproteinemia:
- Treatment of patients with primary dysbetalipoproteinemia (Fredrickson type III) who do not respond adequately to diet
- Homozygous Familial Hypercholesterolemia:
- Reduce total-C and LDL-C in patients with homozygous familial hypercholesterolemia as an adjunct to other lipid-lowering treatments (e.g., LDL apheresis) or if such treatments are unavailable
- Pediatric Patients:
- As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present:
- LDL-C remains ≥190 mg/dL or
- LDL-C remains ≥160 mg/dL and:
- There is a positive family history of premature cardiovascular disease or
- Two or more other cardiovascular disease (CVD) risk factors are present in the pediatric patients
- As an adjunct to diet to reduce total-C, LDL-C, and apo B levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia if after an adequate trial of diet therapy the following findings are present:
- Heterozygous Familial and Nonfamilial Hypercholesterolemia: